MIRA INFORM REPORT

 

 

Report Date :

29.01.2013

 

IDENTIFICATION DETAILS

 

Name :

GENOMMA LABORATORIES ARGENTINA S.A.

 

 

Registered Office :

Av. Gral Las Heras 1947, Piso 6º, CABA.

 

 

Country :

Argentina

 

 

Date of Incorporation :

25.04.2007

 

 

Legal Form :

Public Limited Company

 

 

Line of Business :

Medicinal Product Development for Use Human

 

 

No. of Employees :

68

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit:

USD $ 185.000

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Argentina

B1

B1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

argentina - ECONOMIC OVERVIEW

 

Argentina benefits from rich natural resources, a highly literate population, an export-oriented agricultural sector, and a diversified industrial base. Although one of the world's wealthiest countries 100 years ago, Argentina suffered during most of the 20th century from recurring economic crises, persistent fiscal and current account deficits, high inflation, mounting external debt, and capital flight. A severe depression, growing public and external indebtedness, and a bank run culminated in 2001 in the most serious economic, social, and political crisis in the country's turbulent history. Interim President Adolfo RODRIGUEZ SAA declared a default - the largest in history - on the government's foreign debt in December of that year, and abruptly resigned only a few days after taking office. His successor, Eduardo DUHALDE, announced an end to the peso's decade-long 1-to-1 peg to the US dollar in early 2002. The economy bottomed out that year, with real GDP 18% smaller than in 1998 and almost 60% of Argentines under the poverty line. Real GDP rebounded to grow by an average 8.5% annually over the subsequent six years, taking advantage of previously idled industrial capacity and labor, an audacious debt restructuring and reduced debt burden, excellent international financial conditions, and expansionary monetary and fiscal policies. Inflation also increased, however, during the administration of President Nestor KIRCHNER, which responded with price restraints on businesses, as well as export taxes and restraints, and beginning in early 2007, with understating inflation data. Cristina FERNANDEZ DE KIRCHNER succeeded her husband as President in late 2007, and the rapid economic growth of previous years began to slow sharply the following year as government policies held back exports and the world economy fell into recession. The economy has rebounded strongly from the 2009 recession, but the government's continued reliance on expansionary fiscal and monetary policies risks exacerbating already high inflation.

 

Source : CIA

 

Registered Name 

 

GENOMMA LABORATORIES ARGENTINA S.A.

C.U.I.T. 30-71012195-4

 

 

Summary 

 

INCORPORATED IN 2007. BEGINNER OF ACTIVITIES. IT DOESN'T SUPPLY FINANCIAL INFORMATION. STABLE PERSPECTIVES. IT FULFILLS ITS COMMITMENTS. FIT FOR  CREDITS WITH ADDITIONAL SECURITIES.

 

 

Operations 

  

MEDICINAL PRODUCT DEVELOPMENT FOR USE HUMAN.

 

 

Legal Structure 

 

LEGAL FORM:                          PUBLIC LIMITED COMPANY
CREATED:                                25/04/2007
REGISTERED RPC:                 15/05/2007
DURATION:                               99 YEARS
END OF FISCAL YEAR:            31/12
AFIP:                                                    Nº 56, AV.DEL LIBERTADOR 1436, VTE LOPEZ, PCIA DE BS.AS.

 

 

Contact 

 

Mr. FEDERICO LAPORTE. (Administracion)

Legal address: Av. Gral Las Heras 1947, Piso 6º, CABA.

Operative and Administrative address: Domingo de Acassuso 3780, Olivos, (1636) Province of Bs.As., Republic of Argentina.

Phone/fax: 54-11 4801-3080
E-mail: flaporte@genommalab.com.ar
www.genommalab.com.ar

 

 

Partners 

 

PRESIDENT                              MAXIMO JUDA
ALTERNATE DIRECTOR             ALEJANDRO CIERO

Using signature: Paid by the President.

 

 

Corporate Stock 

 

SOCIAL CAPITAL $ 185.000.-

 

 

Personal Information 

 

MAXIMO JUDA:
------------

argentino, single, born 11/10/1976, with DNI Nº 25.598.797.

 

 

History 

 

While the holder is responsible for a wealth of details on the matter, based on data contained in our power is being able to quote it as an initiator of the activities being developed and which is located in the address set forth in the heading.

The head is part of "GROUP GENOMMA", headed by Genomma Laboratories S.A. de C.V. of Mexico, and multiple companies in the world.

 

 

Economic-Financial Position 

 

No provided financial information to third parties.

 

 

Commercial References Consulted 

 

CARTOCOR S.A.
SMURFITT KAPPA S.A.

Credits. u$s 40.000
Payments: 60/90 days.
Concept: Good.

 

 

Evolution and Results 

  

The holder is engaged in the manufacture, packaging, sale, marketing and distribution, import and export of medicinal and pharmaceutical preparations, toiletries, cosmetics, nutritional additives, dietary supplements, veterinary products, disinfectants, chemicals, etc.

Allocate a percentage of its budget for research and development and tried productos.Analizado meet the needs of their consumers to improve their health and wellbeing, by providing them with the latest research and technological advances.

Since its founding Genomma Lab has a close connection with its distribution channels, which is why today reaches several thousand outlets throughout the country. Also exported to over 30 countries and have sales offices in Spain, Argentina, Peru, China and India soon.

PRODUCTS:
---------
ASEPXIA
CICATRICURE
DALAY
GOICOECHEA
BENGUE
DIABET TX
GENOPRAZOL
GOICOTABS
POINTTS
SHOT D
SILKA MEDIC
NIKZON
X RAY
NEXT
BENGUE CAPS
BIO ELECTRO
UNIGASTROZOL
QG5
QUARA
TUKOL D
UNESIA
DERMO PRADA
QUIT
LOMECAN

FOREIGN TRADE:
--------------
In the last twelve months, it has made specific imports by u$s.8.311.053 according to the following detail:

MEXICO         8.049.053
ISRAEL           262.000

* 68 EMPLOYEES.

 Payment Record and Credit Risk 

 

BANCO PATAGONIA            SUC. OLIVOS
STANDARD BANK                   "

CREDIT RISK:
-------------
NOVEMBER 2012

BANCO PATAGONIA      $ 60.483.800

SITUATION 1: NORMAL.

INSURANCE:
----------
LA CAJA S.A.

 

 

Concept 

 

 

It doesn't register delinquencies, trials, protests or other negative.

It fulfills correctly its commercial and bank commitments.

* NOT OBJECTIONS.

 

 

Final Opinion 

 

Keeping in mind its good backgrounds, the company is feasible for credit treatment with appropriate guarantees.

* FIT FOR CREDITS


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.53.89

UK Pound

1

Rs.84.92

Euro

1

Rs.72.51

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.